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resumo 
 
 
A Perturbação de Hiperatividade e Défice de atenção e a Dislexia são doenças 
do neuro-desenvolvimento com uma prevalência muito elevada nas crianças e 
que frequentemente persistem na adolescência e no adulto. Com um 
diagnóstico difícil, baseado em escalas nas quais se quantificam os sinais e 
sintomas, um método de diagnóstico fiável, não invasivo e adequado a 
crianças é apropriado. Para isso, um diagnóstico utilizando amostras de saliva 
com recurso a biomarcadores salivares é o ideal para a população em estudo. 
O estabelecimento do SOP com procedimentos de recolha, processamento e 
armazenamento são essenciais para o uso da saliva. 
Além disso, e uma vez que parece haver relação entre doenças cognitivas e 
inflamação, a avaliação do perfil de proteínas e quantificação de citocinas 
relacionadas com a inflamação são um ponto de partida para entendermos 
estas patologias. A avaliação de duas citocinas CCL3 e CCL13, presentes em 
inflamação, foi realizada com recurso à tecnologia multiplex. Os níveis destas 
duas citocinas encontram-se aumentados em indivíduos multi-comprometidos 
o que nos leva a inferir que a neuroinflamação está presente nestas 
patologias. Estudos futuros devem ser feitos no sentido de validar 
biomarcadores inflamatórios nestas patologias. 
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abstract 
 
The Attention Deficit Hyperactivity Disorder and Dyslexia are 
neurodevelopmental diseases with a very high prevalence in children which 
often persist into adolescence and adulthood. With a difficult diagnosis, based 
on scales quantifying the signs and symptoms, a method of reliable, non-
invasive diagnosis, suitable for children is urgent. A diagnosis using saliva 
samples quantifying salivary biomarkers is ideal for this study population. The 
establishment of the standard operating procedure with procedures for 
collecting, processing and storage of samples is essential to use saliva. 
Furthermore, since there appears to be a relationship between cognitive 
diseases and inflammation, the evaluation of the protein profile and 
quantification of cytokines related to inflammation are a starting point to 
understand the pathology. The evaluation of the chemokine (c-c motif) ligand 
13 (CCL13) and of the chemokine (c-c motif) ligand 3 (CCL3), present in 
inflammation, was done using multiplex technology. The levels of these two 
chemokines are increased in multicompromised individuals which leads us to 
infer that neuroinflammation is present in these pathologies. Future studies 
should be done to validate inflammatory biomarkers in these diseases. 
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1. Introduction 
1.1 Attention deficit hyperactivity disorder 
1.1.1 Characterization of attention deficit hyperactivity disorder 
 
Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder 
defined by a persistent standard of lack of attention and/or hyperactivity-impulsivity 
that interferes with the function of development [1]. Typically, it manifests itself 
early in development, before the child starts school, and is characterized by 
developmental deficits that affect the operation at personal, social, academic and 
occupational levels. It is one of the most common childhood neurobehavioral 
disorders that frequently persist into adolescence and adulthood. In many cases, 
even with intervention, the difficulties persist into adolescence and adulthood with 
deficits that include specific limitations on learning, executive functions, 
intelligence and social skills [2, 3]. The significant functional impairment, poorer 
quality of life, legal problems, grade retention, lower standardized achievement 
scores and grade point averages, failure to graduate high school, increased rates 
of substance abuse and persistent neuropsychological impairments are frequently 
associated with ADHD and represent increased costs to the individual and the 
society [4]. The ADHD occurs in about ~5 to 8% of children and 2.5% of adults.  It 
is more prevalent in men, in a ratio of two to one, but in adolescence this 
discrepancy is attenuated, with both genders presenting a similar prevalence [5]. 
1.1.2 Neurophysiology of ADHD 
 
The cardinal features of ADHD are problems in the domains of the attention, 
impulse and motor control [6]. The brain region involved in the control of action 
and attention include the prefrontal cortex (particularly the dorsolateral cortex), 
striatum (composed by two structures, the caudate and the putamen) and the 
cerebellum (particularly the vermis), regions that are interconnected [6] (Figure 1). 
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Figure 1 - The key components involved in the control of action and attention centers in the 
prefrontal cortex (A), the striatum (B), and the cerebellum (C). Adapted by [6] and from [7]. 
Individuals with ADHD present subtle differences in brain structure, like a 
decreased in volume of the cerebellum [8, 9], and striatum [6]. Measures of brain 
cortical and subcortical volumes show that the cerebrum as a whole is smaller in 
children and adolescents with ADHD [10] (Figure 2).  
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Figure 2 – Comparison between normal brain and ADHD brain. From [11]. 
 
1.1.3 Etiology of the Disease 
 
Family histories of ADHD, preterm birth, smoking or drinking during pregnancy are 
risk factors for developing ADHD [12-14]. Psychological adversity and high levels 
of family conflicts were also associated with the disease [15]. In utero, several 
factors that include the maternal stress during pregnancy [16], prenatal exposure 
to tobacco, alcohol and other drugs and environmental toxins [17, 18], 
pregnancy/birth complications [17], intrauterine growth retardation [19] and low 
birth weight/prematurity have been associated with ADHD.  
Neonatal axonia and seizures, brain injury [17] and exposure to lead [20] are early 
postnatal environmental factors that influence ADHD. 
   
1.1.4 Diagnosis of ADHD 
 
The diagnosis of this pathology is based on clinical observation, but some rating 
scales, such the Conners Rating Scale and the Strengths and Difficulties 
Questionnaire, completed by parents and teachers, can be useful to detect and 
quantify the signs and symptoms [21, 22]. The diagnostic is not easy due to the 
comorbidity with other pathologies like autism spectrum disorder, depression, 
anxiety, bipolar, antisocial and mood disorders [23-25]. An early detection is 
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required for an early intervention, either pharmacological, behavioral or 
pedagogical [5]. Since this pathology manifests itself in children, non-invasive, 
comfortable and pain-free methods to help to diagnose this pathology are 
required. 
1.1.5 Treatment for ADHD 
 
The treatments include pharmacological and/or behavior therapy. The 
pharmacological therapy is considered the first-line treatment for patients with 
severe ADHD and impairment [12]. Medications for these patients (approved by 
the Food and Drug Administration) include stimulant and nonstimulant 
medications. In terms of stimulant medication, there are two categories: 
amphetamines and methylphenidates. Data suggest that amphetamines may be 
moderately more effective than methylphenidates [26].  
Methylphenidate is the most common used and is rapidly absorbed orally. It starts 
to act 20-30 minutes after ingestion and is eliminated quickly, wherein the effect is 
maintained only during 3 or 4 hours [27]. In terms of nonstimulant medication the 
atomoxetine is the most common. Atomoxetine blocks the norepinephrine 
transporter and increases levels of both noradrenalin and dopamine in the 
prefrontal cortex [28]. The principal adverse effects of taking these drugs are 
decreased appetite, headache, dry mouth, insomnia, irritability and dizziness [29].  
1.1.6. ADHD and metabolism 
 
Individuals with ADHD have a deficiency of micronutrients, such as folate, vitamin 
B6, zinc, carnitine, serine, glutamine, choline and antioxidants (Figure 3). 
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Figure 3 - Nutrition correlation status in ADHD. From [30]. 
 
In terms of antioxidant status, individuals with ADHD have a prevalent oxidative 
imbalance and glutathione deficiency is also common. A study correlates the low 
folate status in pregnancy with hyperactivity in children [31]. People with methyl 
tetrahydrafolate reductase gene are predisposed to folate deficiency and are more 
expected to have ADHD [32]. 
Evidences suggest that as Ritalin, high doses of vitamin B6 are effective for 
patients with ADHD, possibly due to its role in raising serotonin levels [33]. This 
vitamin also has a synergistic effect with magnesium. In terms of nutrients, 
deficiency of magnesium leads to poor function of neurotransmitters that control 
emotion, social reactions and attention which are involved in ADHD [34]. Zinc is an 
essential nutrient important in immune system function. Low levels of zinc depress 
melatonin and serotonin production which affect information processing and 
behavior in ADHD [35]. Studies have shown that zinc levels are lower than normal 
in the majority of children with ADHD [36]. Carnitine reduces hyperactivity and 
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improves social behavior in individuals with ADHD due to its role in fatty acid 
metabolism. Carnitine is considered by many a safe alternative to stimulant drugs 
[37]. Administration of phosphatidylserine with omega 3 fatty acids improved 
ADHD symptoms suggesting a synergistic effect [38]. Also, phosphatidylserine 
increases dopamine levels. Glutamine that is the precursor for the 
neurotransmitter gamma-aminobutyric acid affects mood, focus and hyperactivity 
[39]. Disruption of the glutamine-containing neurotransmission systems may cause 
ADHD [39]. Choline a precursor of acetylcholine regulates memory, focus and 
muscle control, areas which are related with hyperactivity [40]. 
1.1.7 Physiopathology of the disease 
 
Several central nervous system abnormalities in ADHD patients confirm the 
neurobiological basis of the disorder. Findings show that other 
neurodevelopmental disorders like autism, schizophrenia, and epilepsy share 
genetic variants with ADHD [41]. The brain sub regions including frontal and 
parietal cortexes, basal ganglia, cerebellum, hippocampus, and corpus callosum 
have been involved in the functional networks related to ADHD [42] (Figure 4).  
 
Figure 4- Schematic representation of functional circuits involved in the pathophysiology of ADHD. 
Here the attention network (green), the fronto-striatal network (yellow), the executive function 
network (black), the fronto-cerebellar network (red), and the reward network (blue) are 
summarized. From [28] 
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ADHD is related to a dysfunction of the circuits at the nervous system level, 
reducing the availability of neurotransmitters like dopamine and noradrenalin [43], 
and these deficits may underlie core symptoms of lack of attention [44] and 
impulsivity [45]. 
1.1.7.1 Membrane trafficking and protein kinases involved in ADHD 
 
There is genetic evidence linking the components of membrane trafficking of 
intracellular vesicles to a variety of neurological conditions including autism and 
ADHD. Dopamine transporter-mediated re-uptake system controls the intensity 
and duration of dopamine actions at synaptic receptors, which provides 
modulatory influences over attention and behavior. Dopamine signaling is a crucial 
risk factor for ADHD, and dopamine transporter may be involved in the 
dopaminergic dysfunction associated with ADHD [46].  
The intra-cellular signaling of dopamine transporter may happen through the 
protein kinase A (PKA) and protein kinase B (AKT) pathways.  AKT is a central 
player in signal transduction activated in response to numerous growth factors and 
is thought to contribute to many important cellular functions, including cell growth, 
apoptosis, nutrient metabolism, and modulating the activity of several transcription 
factors [47] (Figure 5). 
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Figure 5- Phosphoinositide 3-kinase/ Protein kinase B/ Phosphatase and tensin homolog signaling. 
PI3K (Phosphoinositide 3-kinase); PTEN (Phosphatase and tensin homolog); AKT (Protein kinase 
B); mTor (mammalian target of rapamycin); From [48]. 
 In addition, a crosstalk between PKA and mammalian target of rapamycin 
(mTOR) pathway in apoptosis resistance signaling has been reported [86]. mTOR 
is a conserved serine/threonine kinase within the cells that controls protein 
synthesis and cell growth and is involved in neurological disorders including ADHD 
and autism [49]. Two mTOR complexes (1 and 2) are also involved in ADHD and 
autism. Deregulation in mTOR signaling, namely the loss of mTORC2 signaling 
lead to disrupt normal brain development and its function. mTORC2 has a role in 
neuronal size control and its deregulation affects function, size and connectivity of 
neurons [50]. 
The critical role of protein kinases in brain development has been investigated for 
decades.  A study done in rats shows that PKA inhibition within the medial 
prefrontal cortex produces inattention and hyperactivity, and might modulate 
human attention disorders. Considering the implication of protein kinases in 
ADHD, it is important to understand the effect of each one in inflammatory 
responses in the brain. PKA controls the expression of some key cytokines like 
interleukin (IL)-6 an interleukin that acts as a pro-inflammatory and anti-
inflammatory cytokine.  
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Both activation and inhibition of the two kinases if they work one-sidely, may not 
contribute to the improvement of neuronal disorders [48] (Figure 6).  
 
 
Figure 6- Scheme of protein kinases PKA and AKT modulation in the pathogenesis of autisms and 
ADHD. Star faces represent an image of the individual kinase activities. Sad faces mean 
unbalance of kinase activity. PKA (Protein kinase A); AKT (Protein kinase B); SNPs (Single 
Nucleotide Polymorphisms); CADM1 (cell adhesion molecule 1); DAT (Dopamine Transporter); 
ADHD (Attention Deficit Hyperactivity disorder). In [48]. 
 
The alteration of the functions in neurobeachin, cell adhesion molecule 1 and 
dopamine transporter with genetic deletion and/or single nucleotide 
polymorphisms may change the activity or selectivity of these kinases to 
substrates, which in turn may cause the psychological disorders [48].  
The balance between PKA and AKT kinases may be essential for their function. 
Several food and/or dietary components can contribute to the balance via the 
modulation of kinase activities [48]. These findings might be translated into new 
dietary managements for the treatment of diseases like autisms and ADHD in the 
future [48]. ADHD has been suggested to be related to a deficiency of the omega-
3 long-chain polyunsaturated fatty acids [51]. ω-3 long-chain polyunsaturated fatty 
acids low levels in blood have been reported in children with ADHD and related to 
learning difficulties, suggesting benefits from dietary supplementation [52]. 
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Recent studies highlight the contribution of the intestinal flora to psychiatric 
diseases [53, 54]. The brain and the gut form an axis of two-way communication 
[55], and the alteration of this axis can lead to psychiatric disorders such as 
perturbations of the autism spectra [56], mood disorders, anxiety and depression 
[55, 57]. 
 
1.1.8 Link between ADHD and Inflammation 
 
Increasing evidence indicates that brain inflammation is important in the 
pathogenesis of neuropsychiatric disorders [58-60]. Brain inflammation is a 
commonly complex process involving several types of cells, including microglia, 
monocytes, neutrophils, astrocytes and neurons [61]. Until recently, it was thought 
that the microglia, resident brain macrophages, was the only cell mediating brain 
inflammation. However, recently it was shown that neutrophils and monocytes 
infiltrate the injured brain and contribute to inflammation. Neurons and astrocytes 
also participate in brain inflammation [62]. The astrocytes are responsible for 
producing anti-inflammatory factors [63, 64] and chemokines that recruit 
monocytes [65]. Neurons regulate the inflammation positively and negatively [66]. 
Microglia, in response to injury, isolate damaged areas and prevent propagation of 
disrupted injury sites and express chemokines and growth factors that support 
survival of surrounding neurons. Then, neutrophils infiltrate in case of risk of 
infection. Thereafter, monocytes infiltrate, helping to repair brain damage [61].  
The activation of the innate immune signaling pathways in microglial cells occurs 
in response to infectious organisms, during brain injury and chronic disease [67]. 
Similarly to macrophages, microglial cells express toll-like receptors (TLRs), 
respond to TLR ligands and produce pro-inflammatory mediators [68, 69]. 
Microglial cells can be activated during systemic infections without the integrity of 
the blood-brain barrier being compromised. In regions where there is no blood-
brain barrier, the response to circulating pathogens is similar to that in most 
systemic organs [67].  
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Microglia comprises a rather large cell population and distinct stimuli trigger 
distinct responses (Figure 7).  
 
 
Figure 7- Microglia response heterogeneity. (A) The stimulation of microglia by neurotransmitters 
and neurohormones trigger calcium (Ca
2+
) signals. (B) Exposure to lipopolysaccharides (LPS) 
induce a population expression of major histocompatibility complex 1 (MHCI) molecules. All 
microglia cells express TLR4 but only some subsets produce TNF-α and/or CCL3. (C) The 
stimulation by interferon gamma (IFN-γ) gamma causes the expression of major histocompatibility 
complex II (MHCII) in some cells. (D) Exposure of microglia to myelin debris results in phagocytic 
uptake of the material. In [70]. 
The microglial diversity when stimulated by neurotransmitters and hormones 
(Figure 7A) triggers calcium signals. Exposure to lipopolysaccharides (LPS) 
(Figure 7B) induces a population expression of major histocompatibility complex 1 
(MHC class I) molecules. Almost all cells showed TLR4-mediated induction of 
MHCI. Stimulation of mouse microglial TLR4 trigger the panpopulation 
upregulation of MHC class I, required for antigen presentation to cytotoxic T cells.  
This TLR4 activation leads to the release of TNF-α. At a single cell level, only a 
subpopulation can carries this activity, the demarcation of the subpopulation gets 
sharper with increased postnatal age. That includes chemokine (C-C motif) ligand 
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(CCL) 3 as a T cell-attracting chemokines. Concluding, all microglia cells express 
TLR4 but only some subsets produce TNF-α and/or CCL3.  
 
The stimulation by Interferon gamma (Figure 7C) causes the expression of major 
histocompatibility complex II (MHC class II) structures for antigen presentation in 
some cells.  Exposure of microglia to myelin debris (Figure 7D) results in the 
phagocytic uptake of the materials. 
Microglia response heterogeneity may itself be part of the pathogenic process or 
rather an attempt to contain its aggravation. 
 
Depression, anxiety, sleep disorders and dyslexia are often associated with 
ADHD.  Evidences suggest that hyperactive individuals are commonly anxious and 
depressive, and these two conditions have been suggested to be associated with 
systemic inflammation up-regulation [71]. There is an association between anxiety 
characteristics and inflammatory biomarkers such C reactive protein, interleukin-6 
(IL-6) and cortisol. [72, 73] The levels of c reactive protein are increased only in 
anxious and depressive men [72]. In anxious individuals, the levels of morning 
cortisol are lower and the levels of the pro-inflammatory IL-6 are higher [73].  
There is evidence indicating that inflammation underlies other neurological 
pathologies, such as dementia [74], Alzheimer’s disease (AD) [75], depression [76] 
and psychological stress [77]. However, there is a lack of molecular data. 
Evidences indicate that systemic infection has an impact on the inflammatory 
diseases of the central nervous system which influence the disease process and 
the neurological function [78]. Systemic infections increase cytokines synthesis 
[79] and these circulating cytokines and other inflammatory mediators can affect 
the brain by several routes [78]. Circulating cytokines like IL1β, IL-6 and TNF-α 
cannot penetrate the blood brain barrier [80], thus they communicate with the brain 
centers through the cerebral endothelium and act on brain through the 
circumventricular organs [80] and the vagus nerve to effect local cytokine and 
prostaglandin synthesis and produce sickness behaviours. 
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1.1.9 Chemokines 
 
Microglia and astrocytes are prominent sources of chemokines within the central 
nervous system, but some neurons also produce chemokines. Chemokines are 
important signaling molecules in the central nervous system. They belong to a 
family of small proteins identified for their role in immune system as inflammatory 
and chemoattractive factors. 
There are two types of chemokines: the inflammatory chemokines that control the 
recruitment of leucocytes during infection [81], the interaction with members of the 
G protein-coupled receptor [82], inflammation, tissue injury and play a role in T cell 
activation and development [83, 84] and the homeostatic chemokines that 
navigate leucocytes during hematopoiesis in the bone marrow and thymus [85]. 
1.1.9.1  Chemokine CCL3 
 
CCL3 is a 7.8 kDa protein that is up regulated in the hippocampus of temporal 
lobe epilepsy patients [86]. The increased levels of CCL3 occur during 
epileptogenesis in animal models of temporal lobe epilepsy which suggest a role 
for CCL3 in this condition [87]. CCL3 has also been implicated in head injury [88], 
ischemia [89], AD [90] and HIV infection [91]. 
Functional properties of central nervous system neurons could be altered by CCL3 
if subjected to prolonged exposure of this chemokine in the central nervous 
system, as occurs during CNS neuroinflammation [92]. 
1.1.9.2  Chemokine CCL13 
 
CCL13 is a member of a distinct, structurally related subclass of chemoattractants 
chemokines mainly involved in recruitment of eosinophils, basophils monocytes 
and T lymphocytes to inflammatory sites [93]. 
This chemokine is up-regulated at sites of inflammation and may play a major role 
in the pathophysiological mechanisms of allergic disorders such asthma [94] and 
atopic dermatitis [95], which are considered to be Th2 dominant diseases. 
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Expression of CCL13 protein is greater in the sputum, epithelium, submucosal 
inflammatory cells and bronchoalveolar lavage fluid of asthmatics individuals [94]. 
CCL13 is a chemokine that has been detected and quantified in blood [93] and it is 
also highly expressed in cartilage from patients with rheumatoid arthritis [96]. 
1.2. Characterization of dyslexia 
 
Reading disorders like dyslexia and attention deficits often co-occur [97]. Dyslexia 
is a neurodevelopmental disorder characterized by slow and inaccurate word 
recognition and spelling [98]. Individuals with this pathology have difficulties with 
decoding regardless of adequate instruction, intelligence and intact sensory 
abilities and comprehension [98]. Dyslexia can result from brain damage (acquired 
dyslexia) or be present before reading acquisition (developmental dyslexia) [97]. 
The definition of dyslexia assumes that the disorder is neurobiological in origin 
with strong evidence for heritability, but environmental factors shape the risk for 
the disease [99]. The prevalence of dyslexia in school-age children ranges 
between 6% and 17% [100]. The signs and symptoms of this pathology are 
caused by a deficit in specific language skills responsible for processing 
phonological information [101]. The diagnosis is done after the individual is 
exposed to formal literacy instruction. [102, 103]. Dyslexic males have higher rates 
of comorbid disorders such as ADHD and come to clinical attention more often 
than females, which can indicate the risk for later reading problems [104, 105]. 
This pathology can be prevented in children with an early intervention [99].  
Detecting reading disorders like dyslexia as early as possible may help individuals 
to overcome reading and learning problems. A study identifies a specific gene, 
DYX1C1, as a candidate susceptibility gene for developmental dyslexia. This gene 
encodes a nuclear tetratricopeptide repeat domain protein dynamically regulated 
in brain. The DYX1C1 protein appears to be rapidly up-regulated and translocated 
after brain ischemia [106].  
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1.3 Saliva as a diagnostic fluid  
 
Human saliva is a complex body fluid composed by an exocrine contribution from 
the major and minor salivary glands and by non-exocrine components that 
comprise microorganisms, desquamated oral epithelial cells and leukocytes [107, 
108] . As main functions, saliva participates in the mastication, deglutition, speech, 
lubrication, with functions in ionic balance regulation, and antibacterial, antifungal 
and antiviral activities [109]. 
There is a growing interest in the use of human whole saliva for diagnostic and 
disease monitoring as an alternative to blood samples [107]. Consequently, a 
large number of analytes in saliva were gradually unveiled and some are 
biomarkers of different diseases [110].  
The utility and usability of saliva as diagnostic fluid has been studied by 
researchers and several Omics saliva studies have led to the production of 
massive amounts of data collected and annotated in databases on the 
identification and characterization of the different salivary components (DNA, RNA, 
proteins, metabolites and microorganisms) [111]. Saliva reflects the health or 
disease state [112-123] of an individual.  The advantages of using saliva relatively 
to other fluids (blood, serum or plasma), which include the simple, non-invasive 
and safer sampling methods that require minimal equipment and easy and 
inexpensive storage possibilities.   
Contrary to other sterile fluids, like the cerebrospinal fluid [124], blood, amniotic 
and pleural fluid, saliva is not sterile [107] and therefore it is subjected to microbial 
degradation which influences sample quality [125]. Nonetheless the effect of saliva 
collection, preparation and storage methods on the amount of microbial derived 
degradation hasn’t been extensively studied. Furthermore, some parameters such 
as diurnal, inter and intra individual variation on the different components haven´t 
been definitely established. In fact, even though for some proteins and steroid 
hormones there are data supporting diurnal variations [126-128] for other proteins, 
total volume and protein concentration [126, 129] the quantifications seem to be 
independent of the circadian cycle [127].  
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1.4 Biobanks 
 
Biobanks comprise organized collections of biospecimens (tissue, blood, urine, 
plasma, saliva) annotated with personal and clinical information and are a 
fundamental resource for high quality academic research and translational 
medicine [130, 131]. The development and validation of analytical methods, 
diagnostic tests and biomarker discovery depends on good quality repositories 
[124]. Two main concerns of biobank managers are sample preservation and 
annotation quality and consistency, both of which are dependent on the 
standardization of the collection, processing and storage protocols [130]. 
There are different types of biobanks depending not only on the biospecimens 
they store, but also on the research purposes they serve [124]. Biobanks range 
from project driven biobanks to more general repositories which function as a 
reference collection to address different and not predetermined questions or 
specific research purposes [132].  
In the 2000s about 43 biobanks were created around the world [124]. In Portugal 
the major Biobank is established in the Lisbon Academic Medical Centre [133]. 
This biobank has been previously described [134] and includes mainly blood 
derived specimens. Recently, as the result of a partnership with the Departamento 
de Ciências da Saúde of the Universidade Católica Portuguesa, it has started to 
store saliva samples. 
 
1.5 Salivary Biomarkers  
 
Efforts are made to development and validation of biomarkers to facilitate the 
identification of novel and effective treatment and strategies for several diseases. 
[135] Biomarkers are entities within the body capable of providing information 
regarding the current physiological state of an organism [136].  By definition, a 
biomarker is a biological characteristic that is objectively measured and evaluated 
as an indicator of normal biological or pathologic processes [137]. These 
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biomarkers exist in a variety of forms like antibodies, microbes, DNA, RNA, lipids, 
metabolites and proteins [138]. Potential biomarkers discovered in omic libraries 
(proteomic, transcriptomic, metabolomic, epigenomic) must be subjected to 
comprehensive evaluation and validation [139]. A biomarker should be reliable, 
reproducible, noninvasive, simple to perform and inexpensive. The onset, 
progression or regression of a disease can be associated with the alteration of the 
concentration, structure, function, or action of biomarkers [138]. Concluding, a 
biomarker is a valuable and attractive tool for detection, risk assessment, 
diagnostic, prognostic and monitoring of disease [140]. The analysis of protein 
levels as a source of differentially expressed proteins that represent biomarkers 
has become an established field of research [141]. Protein biomarkers can be 
studied in neuropsychiatric disorders [142].In those cases, proteomic research is 
focused on comparing protein expression levels between patients and healthy 
controls.  
 
1.5 The Bioinformatic tool OralCard  
 
Bioinformatics has became a central core that integrates the disparate bodies of 
data, scientific knowledge and computational infrastructure from genetics, 
structural biology and medical and animal models of disease [143]. OralCard is a 
bioinformatic tool dedicated to scientific research in oral health; this tool allows the 
analysis and integration of data from oral proteomes, contributing to the 
elucidation of oral biology and to the design of strategies for the identification of 
biomarkers for oral and systemic diseases [111]. OralCard collects information on 
proteins present in the oral cavity [111]. When searching for protein name or its 
UniProt code, OralCard retrieves information about the protein providing 
associations between proteins, diseases, pathways, gene ontologies and 
organisms. Integrating all this information, allows the user to perform queries in a 
fast and intuitive way [111]. In this dissertation, OralCard is used since it gathers 
data about the proteome of the oral cavity and because proteins are used as 
potential biomarkers. In the context of this study, OralCard will be updated with 
proteins that are associated with neuropsychiatric diseases will be carried out. 
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2. Objective 
The objective of this dissertation is to establish the methodology for identification 
of inflammatory molecular markers in ADHD and dyslexia using unstimulated 
whole saliva as a diagnostic body fluid.  
In order to fulfill the objectives, a series of tasks will be performed: 
 
 Establish the methodology to create a standard operating procedure (SOP) 
for the collection, the processment and the quality control of saliva samples. 
 Update OralCard database with proteins reported to be involved in 
neuropsychiatric diseases. 
 Compare the overall profile of proteins present in the saliva of healthy 
donors with ADHD and dyslexia.  
 Contribute to the establishment of a collection of saliva samples of children 
with ADHD and dyslexia within the Instituto de Medicina Molecular (IMM) 
collection biobank.  
 Evaluate two chemokines CCL3 e CCL13 which are related with the 
inflammatory response. 
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3. Materials and Methods 
In the flowchart below (Figure 8) the methodology used in this study is 
summarized. 
 
 
Figure 8 - Flowchart that shows the work developed. The first part concerns the establishment of 
the SOP and the second part the comparison of the different profiles of samples (healthy, 
hyperactivity, dyslexia and multi-compromised individuals). Image prepared with yEd Graph Editor 
version 3.14.2. 
There are several methods to collect saliva samples [112, 144-146]. However, 
despite several published methods a comparison of several methods to establish 
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one protocol wasn´t available. For the establishment of the SOP, it is necessary to 
select a collection method and site as well as the characterization of the impact of 
the circadian variability on the volume, protein concentration, pH and protein 
profile of the collected saliva. The evaluation of inter and intra individual variability 
complements the evidence necessary to establish a SOP guaranteeing the 
preliminary quality control characterization of the saliva. 
3.1 Participants and ethics statements  
 
For the establishment of the SOP, saliva samples were collected at Universidade 
Católica Portuguesa on 22 healthy volunteers (9 males and 13 females) aged 
between 19 and 27 years old (mean=21 years; SD=2.34). This is a convenience 
sample representative of the university students.  
For the identification of inflammatory biomarkers in ADHD, saliva samples were 
collected at Centro de Hiperatividade and Centro de Dislexia of Universidade 
Católica Portuguesa and in the Agrupamento de Escolas Viseu Sul on 27 
volunteers aged between 7 and 16 years old (mean=12 years; SD=2.27). The 
study population was composed of 13 males and 14 females. Many hyperactive 
individuals may also have dyslexia. The creation of a group with dyslexia was 
extremely important to distinguish these two pathologies which are often 
associated.  The 27 subjects were divided into four groups: 1-healthy subjects (7); 
2- hyperactive individuals (10); 3- dyslexic individuals (5) and 4- individuals with 
hyperactive and dyslexia (5). 
Donors or their legal representatives consented to the collection and storage of the 
samples and associated data by signing an informed consent (Annex 1) approved 
by the Ethics Commission of the Centro Hospitalar Lisboa Norte – Hospital de 
Santa Maria. The clinical database in which these data are deposited is authorized 
by the National Commission for Data Protection [133]. At the time of sample 
collection a questionnaire (Annex 2) was completed by all subjects/participants 
and archived with the respective serial number on a database created for this 
purpose as well as data that characterizes the samples. In the selection of 
participants, the exclusion criteria were presence of any systemic illness and 
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antibiotic medication during the previous 3 months. The control group was 
composed by healthy individuals with the same age of the groups with the 
pathologies. 
 
3.2 Saliva sample collection methods  
 
For the comparison of collection methods, unstimulated whole saliva of 8 healthy 
subjects was collected in the morning and in the afternoon in two different days 
with a total of 36 samples. Subjects were asked to refrain from eating, drinking or 
have oral hygiene procedures 1h prior to saliva collection. Immediately before 
saliva collection, the subjects were asked to rinse the mouth with clean water for 
30 seconds. This cleaning step is crucial to remove desquamated epithelial cells, 
food and drink remnants. After the mouth rinse, subjects were asked to wait for a 
minute before collection was performed. Saliva was collected by three different 
methods: passive drooling, sublingual cotton-roll and vestibular cotton-roll [147]. 
 
3.2.1 Passive drooling method 
 
In this method, a 50mL sterile tube was used to collect passive drooled saliva for 3 
minutes. The 50mL tube was maintained on ice during collection to ensure the 
integrity of the sample.  
 
3.2.2 Cotton-roll based methods 
 
In these methods sublingual or vestibular saliva was collected with two cotton rolls 
which were placed under the tongue or the vestibular area respectively, for 2 
minutes. The cotton rolls were collected and placed inside a 15mL sterile plastic 
tube with a sterile P100 pipette tip in the bottom (Figure 9) to facilitate saliva 
collection by a centrifugation step at 10000 x g for 10min at 4ºC.  
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Figure 9 – Test tube used for the collection of saliva samples. 
Each sample was characterized as to total volume collected and protein 
concentration. After re-suspension by vortex the total volume is divided in 50µl 
aliquots stored at – 80ºC.  
 
3.3 Selection of saliva collection methods 
 
The characterization of the saliva samples obtained with the three collection 
methods was carried out on 8 samples from healthy subjects based on the total 
volume of saliva and the protein concentration. 
Saliva volume was measured. Protein concentration was determined using 5μL of 
each sample with the protein ultraviolet (UV) program of a NanoVue 
Spectrophotometer (Life Science, GE Healthcare, UK). NanoVue can determine 
protein concentration at 280 nm and use the equation:  
Protein (mg/mL) = 1.55  Abs280nm – 0.76. 
 
3.4 The inter and intra-individual variability and the circadian effect  
 
Upon the establishment of the collection procedure (sublingual method), inter-
individual variation and the circadian effect regarding saliva volume and protein 
concentration were assessed. The number of subjects where increased to 22 (the 
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same 8 subjects more 14 other subjects) to gain statistical power. Protein 
concentration and volume were evaluated individually comparing morning and 
afternoon samples with 22 healthy subjects. 
The evaluation of the intra and inter individual variability was performed on the 
same 8 healthy subjects increasing the morning collection in 11 different times 
(during 5months). Total volume and protein concentration were determined. 
A Cluster to compare variability between individuals was performed. To construct 
the dendrogram we used the program PermutMatrix 1.9.3, the algorithm Ward's 
and the data about the protein concentration obtained by capillary electrophoresis 
and the molecular weight (MW) [148]. 
 
3.5 Evaluation of the protein saliva profile 
 
Capillary electrophoresis using a Experion Automated Electrophoresis System 
(BioRad) with standard protein chips (Experion™ Pro260 Analysis Kit, #7007102, 
BioRad) were used to evaluate the electrophoretic protein profile of each sample 
and for protein band quantification. The chip runs were performed according to 
BioRad technical specifications. Briefly, to all saliva samples sample buffer 
(#7007102, BioRad) with β-mercaptoethanol was added. The saliva samples and 
the ladder (#7007102, BioRad) were subjected to the same denaturing conditions 
(95º-100ºC for 3-5min). The ladder ranges from 10 to 150kDa. The dilutions of 
saliva samples were done with ultrapure water. The migration times and the 
concentration of each protein in the sample wells were normalized to the ladder 
using internal markers present in each sample and in the ladder well.  
3.6 Identification of saliva proteins by mass spectrometry analysis 
 
For protein processing, samples were denatured using Laemmli buffer (BioRad) 
containing sodium dodecyl sulfate with dithiothreitol, alkylated with acrylamide and 
resolved by gel-electrophoresis (short-GeLC [149]).  
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Entire gel lane was sliced, digested with trypsin and peptides were extracted. This 
complex mixture of peptides was then analyzed by LC-MS/MS micro-reversed-
phase at low pH coupled to a high resolution mass spectrometer (Triple TOFTM 
5600 ABSciex®). Peptide fragmentation spectra were generated for protein 
identification using ProteinPilot software (ABSciex®) against Uniprot.  
 
3.7 Update of OralCard database 
 
A review of the literature related to proteins involved in neuropsiquiatric diseases 
was made. A literature search was performed using the search engine aid NCBI - 
PubMed (http://www.ncbi.nlm.nih.gov/pubmed) and with the read cube. For the 
research were used keywords such as ADHD, autism spectrum disorders, 
proteomics, neurodevelopmental disorderd and schizophrenia. To analyze and 
visualize graph-oriented genomic complex networks in which these proteins are 
involved, the Cytoscape application version 3.2.1 with ClueGO+CluePedia was 
used.  
 
3.8 Inter individual variability of saliva samples from hyperactive, 
dyslexic and healthy individuals 
 
The sublingual saliva samples were processed according to the SOP established 
and for all samples total volume, protein concentration and pH were determined.  
A pre-evaluation of sample quality was performed by capillary electrophoresis 
using the Experion software version 3.20 (BioRad) with standard protein chips to 
evaluate the integrity of total protein profile.  
To verify if there is a protein profile characteristic of each pathology, in 
multicompromised individuals with ADHD and dyslexia, a dendrogram of each 
protein profile was built. To construct the dendrogram we used the program 
PermutMatrix 1.9.3, the algorithm Ward's and the data about the protein 
25 
 
concentration obtained by capillary electrophoresis and the molecular weight (MW) 
[148]. 
3.9 Quantification of CCL3 and CCL13 chemokines on saliva samples 
 
The multiplex, a reliable technique established on urine [150], saliva [151, 152], 
plasma [153-158], cerebrospinal fluid [158] and blood cultures [159] was used. 
Samples were assayed using multiplex technology, enabling the evaluation and 
quantification of the proteins according to manufacturer’s guidelines, using a 96 
well plate with fluorescent coded magnetic microspheres coated with analyte 
specific capture antibodies. After microspheres have captured the analytes, a 
biotinylated detection antibody binds to that complex.  Streptavidin-phycoerythrin 
then attaches as a reporter molecule. Inside the instrument, magnetic beads are 
held in a monolayer by a magnet, where two lights emitting diode are used to 
excite the internal microsphere dye and the dye of the reporter molecule, 
respectively. A charge-coupled device camera captures these images, which are 
then analyzed by BioPlex Data Pro™ software. The human chemokine assay to 
evaluate and quantify CCL3 (Bio-Plex ProTM Human Chemokine MIP-1α/CCL3 
Set#171BK44MR2) and CCL13 (Bio-Plex ProTM Human Chemokine MCP-
4/CCL13 Set#171BK39MR2) proteins was used. 15 µl of each sample was used 
(diluted 1:4 v:v).  
3.10 Statistical analysis 
 
The statistical analysis was done with GraphPad Prism 6 (GraphPad Software, 
USA) and p<0,05 was used as cut-off for significance. The comparison of 
collection methods was performed on morning and afternoon collections of each 
method with two replicates with a total of 36 saliva samples. In terms of total 
volume, non-parametric Freadman Test was done and Dunn’s test for multiple 
comparisons. For protein concentration, since the data have a normal distribution, 
parametric one way ANOVA was done and for multiple comparisons the Tukey 
test was used. To evaluate if the total volume and total protein are influenced by 
the circadian effect, a paired t-test was done with morning and afternoon samples 
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of 22 individuals. To compare inter-individual and intra-individual variability a two 
way ANOVA was done. After that, the coefficient of variance was measured to 
compare the variance of the proteins that vary.  
With the samples individuals with ADHD, to compare the four groups of 
hyperactivity, dyslexia, hyperactivity with dyslexia and healthy in terms of volume, 
protein concentration and pH, Kruskal-Wallis test of one-Way ANOVA was done. 
Then, with the output data of capillary electrophoresis, a Kruskal-Wallis test of 
one-Way ANOVA was done to do a band-to-band comparison based on the 
different MW (from 9kDa to 240kDa) between the different groups. Then we used 
the Dunn’s multiple comparison test to compare the protein concentration mean of 
each group with the control group that is the healthy group.  
The statistical analysis of data obtained by multiplex technology from CCL3 and 
CCL13 proteins was done by one-way ANOVA. A P value was calculated based 
on Kruskal-Wallis test. The multiple comparisons were done with the Dunn’s 
multiple comparison test. 
3.11 Biobank associated data from individuals and samples 
 
Associated to biobank the IMM saliva collection a database with clinical 
information and the quality of life was developed. The serial number of each 
sample was deposited on an online application named Quartzy 
(https://quartzy.com/) that is an online system for laboratory management (Figure 
10). At Quartzy, each sample is associated to its collection day and time, method 
of collection, pH, volume, protein concentration, the quantity of sample in µl, the 
gender, the birth date and its location on the biobank. 
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Figure 10 – Example of a Quartzy entry. 
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In addition the general information about the donors (birth date, gender, biometric 
data, ethnic, residence area, marital status, education level and profession, 
personal habits of smoking, drinking, exercise and eating habits; disease and 
allergies development, medication, genetic predisposition, lifestyle, scales such 
happiness and satisfaction of life) were assessed through a questionnaire (Annex 
2). This information was also deposited at Qualtrics (www.qualtrics.com/), a 
software-as-a-service company that offers an online platform for generating online 
surveys (Figure 11). 
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Figure 11- Example of a Qualtrics entry 
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4. Results and Discussion  
4.1 Establishment of the standard operating procedure for saliva 
samples 
4.1.1 Selection of a saliva collection method 
 
Comparing the vestibular, sublingual and drooling saliva collection methods 
significant differences between the sublingual and the vestibular methods were 
found. Total volume (Figure 12A; p<0.0001) was significantly different between 
the 3 methods, while protein concentration was not (Figure 12B). In terms of 
volume, there is also a significant difference between vestibular and drooling with  
a p<0.0001 (Figure 12A). In terms of protein concentration, there is a significant 
difference between sublingual and drooling with a p=0.0001 (Figure 12B).  
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Figure 12– Comparison between the three collection methods tested: volume of saliva collected 
(A) and sample protein concentration (B). Volume was analyzed by non-parametric Freadman test 
(Dunn’s test for multiple comparisons) and protein concentration was analyzed by parametric one-
way ANOVA (Tukey test for multiple comparisons). Statistical analysis was performed on data from 
36 saliva collections for each method, with morning and afternoon collections. 
 
Considering these results, the sublingual cotton-roll method for saliva collection 
was selected for the subsequent saliva collection since it ensures a suitable 
sample volume and protein concentration in only in 2 minutes. This method is easy 
to carry out and friendly to the patient; furthermore, the fact that the cotton-roll acts 
like a filter helps to eliminate cell debris and protein aggregates, allowing a good 
quality sample. It is an easy method to perform in any laboratory since it requires 
minimal non expensive materials and equipment which is an advantage in large 
population studies. Nowadays, there are several oral fluid collector and 
commercial devices [160]  available on the market, however these are expensive.  
The sample volume and protein concentration, are important factors to have into 
account when saliva samples are collected. A good method should ensure a good 
volume (>1mL) and a good protein concentration (>1000µg/mL) of samples. The 
effect of the collection method on protein concentration should be evaluated and 
considered. 
Results from the paired t-test comparing the circadian effect on morning and 
afternoon collections are presented in Figure 13 in terms of the effect on the 
volume (Figure 13A) and protein concentration (Figure 13B).  
Our results didn’t show any difference between morning and afternoon collections 
in terms of protein concentration. However there are differences in terms of 
collected volume, wherein the afternoon sample volume mean is larger than the 
morning sample volume.  There are many studies of circadian variations in the 
salivary flow rate and concentrations of particular ions of human saliva. For some 
proteins like like histatin1,3 and 5, cortisol and statherin and steroid hormones 
there are data supporting diurnal variations [126-128] while for other proteins, total 
volume and protein concentration in terms of the quantifications seems to be 
independent of the circadian cycle [127]. The collection must be done in the 
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morning since for certain proteins like alpha-amylase, cortisol, histatins and 
statherins there is a circadian rhythm associated [126-128]. 
 
 
Figure 13- Circadian variability regarding sample volume (A) and protein concentration (B) for 
morning and afternoon collections. Statistical analysis was performed by Paired t test. Statistical 
analysis performed on data from 22 morning saliva collections. 
 
 
4.1.2 Inter and intra individual saliva characteristics variability 
  
Comparing inter and intra individual variation, the results for volume show that 
there is statistical significance between individuals (p<0.0001) and in intra 
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individual variability (p<0.0001) (Figure 14A). For protein concentration there is 
statistical significance between individuals (p <0.0001) and there is also statistical 
significance within the same individual (p<0.0001) (Figure 14B). In terms of total 
variation, the inter-individual variability overlaps the intra-individual variability in 
both total protein and volume. 
 
Figure 14- Box-plot of inter individual and intra individual variability on sample colume (A) and 
protein concentration (B). The results correspond to saliva samples from 8 donors from which 
samples were collected at 11 different times (during 5 months). Statistical analysis was performed 
by a two-Way ANOVA. 
 
The electrophoretic protein profile of the same 8 healthy individuals analysed 
above is shown in Figure 15 to ascertain if there is a distinct protein profile in 
healthy individuals.  
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After the protein profile analysis, it was verified that some bands are common for 
all subjects (bands with 64 and 70 kDa, Figure 15 grey arrows) and others vary 
widely (37 and 30 kDa, Figure 15 black arrows).  
 
Figure 15- Inter-individual variability of protein electrophoretic profile. The protein profile from 8 
different individuals (the same of Figure 7) analyzed by capillary electrophoresis using the Experion 
BioRad System.  (L) Ladder with a range from 10 to 150 kDa. 
 
From the previous results we concluded that there is an inter individual variability. 
Therefore, we analyze the variance of the protein profile of the 22 subjects 
considering samples collected on morning (Figure 16). The concentration of each 
band is shown. The variability of the different bands is shown for the different MW. 
The proteins that appear in all individuals (white circles) are in the 13, 16, 28, 47 
and 62 kDa range.  
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Figure 16- Distribution of protein concentration for each MW corresponding to the different bands 
obtained in the electrophoretic profile. The bars show the % of coefficient of variance (CV) for each 
group of proteins. The white circles identify the proteins that appear in all individuals studied. 
Samples of 22 healthy individuals were used to identify the more distinct groups of 
proteins. The identification of inter individual protein profile variability is important 
to determine which proteins remain relatively unchanged in different individuals 
and which proteins vary widely. Proteins that are common to all samples 
regardless of the individual are good targets to look for variations between healthy 
and sick individuals.  
The clusters obtained according to the protein profile are present in Figure 17. 
The columns represent the different individuals (1-22) and the rows different MW 
bands. This representation shows that there are two main groups of profiles and 
these are divided into others groups of closer profiles. 
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Figure 17- Heatmap visualizing the level of 19 bands differentially represented between subjects. 
Each column represents the data of protein concentration for all subjects. Rows represent the 
different MW. The color code is graduated from black (under-representation compared to the group 
mean) to grey (over-representation compared to the group mean). Hierarchical clustering analysis 
was used to organize the map. The Cluster is done with the PermutMatrix program using the 
Ward's minimum variance method (n=22).  
4.1.3 Identification of proteins present in saliva  
 
Saliva proteins were identified by mass spectrometry. A pool of 1012 peptides that 
correspond to 60 human proteins was identified and are presented in table 1. The 
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proteins are organized by their MW and UniProt code. The table also shows the 
proteins that are previously identified by other authors and are catalogued in 
OralCard database [111].  
After that, with the proteins identified by MS in saliva samples a Cytoscape 
network was made with the objective of knowing the biological processes in which 
the proteins are involved. The pie chart of biological processes is presented in 
Figure 18. 
The majority of proteins are involved in defense responses to fungi (left side of pie 
chart in purple), others in nicotinamide adenine dinucleotide metabolic process 
(right side of pie in fuschia) and in positive regulation of respiratory burst (pie chart 
in red). There are also proteins involved in retina homeostasis, detection of 
chemical stimulus, tissue regeneration, platelet degranulation and inflammatory 
response to antigenic stimulus.  
 
Figure 18- Pie chart of the human GO: Biological Processes represented on ClueGO+CluePedia 
of the proteins identified by mass spectrometry. The ** represents that there are a statistical 
significance of enrichment; the proteins presented in these processes are significantly increased in 
relation to the others. Image generated by Cytoscape (ClueGO+CluePedia) on June 22, 2015. 
 
In a health situation these proteins are involved in these 10 processes. What is 
expected is that some proteins may be increased/decreased or absent/present in 
disease situations. 
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Table 1- Human salivary proteins identified by Mass Spectrometry analysis. The table shows the protein according to UniProt Code, MW, proteins 
deposited in the OralCard [111] and identified in whole saliva.  
Mol. Wt. 
(kDa) 
UniProt 
Code 
Protein Name 
OralCard Identified 
in whole 
saliva 
 
189 P01024 Complement C3 - fragment  x x 
161 A8K2U0 Alpha-2-macroglobulin-like protein 1  x x 
118 P22314 Ubiquitin-like modifier-activating enzyme 1  x x 
103 P55786 Puromycin-sensitive aminopeptidase (PSA)  x x 
86 P06396 Gelsolin (AGEL)  x x 
83 P01833 Polymeric immunoglobulin receptor (PIgR) x x 
80 P22079 Lactoperoxidase (LPO)  x x 
78 P02788 Lactotransferrin (Lactoferrin) x x 
77 Q06AH7 Transferrin  
  
77 Q08188 Protein-glutamine gamma-glutamyltransferase E  x x 
69 P02768 Serum albumin x x 
69 P15311 Ezrin (Cytovillin)  x x 
58 P14618 Pyruvate kinase PKM  x x 
58 P04745 Alpha-amylase 1 x x 
57 P07237 Protein disulfide-isomerase (PDI) x x 
54 Q9UBG3 Cornulin x x 
53 P52209 6-phosphogluconate dehydrogenase x x 
50 P80303 Nucleobindin-2  x x 
49 P01871 Ig mu chain C region x x 
49 Q8N4F0 BPI fold-containing family B member 2 x x 
47 P06733 Enolase 1  x x 
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47 P01009 Alpha-1-antitrypsin x x 
44 Q9UIV8 Serpin B13  x x 
43 P30740 Leukocyte elastase inhibitor (LEI) x x 
39 P04083 Annexin A1 x x 
38 P01876 Ig alpha-1 chain C region x x 
38 Q6P5S2 Protein LEG1 homolog  x x 
37 P00338 L-lactate dehydrogenase A chain (LDH-A)  x x 
37 P01877 Ig alpha-2 chain C region x x 
36 P01857 Ig gamma-1 chain C region x x 
36 P04406 Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) x x 
35 P23280 Carbonic anhydrase 6  x x 
34 P25311 Zinc-alpha-2-glycoprotein (Zn-alpha-2-GP) x x 
32 Q96DR5 Parotid secretory protein -fragment (PSP)  x x 
29 P18669 Phosphoglycerate mutase  x x 
29 P06870 Kallikrein-1  x x 
28 P31947 14-3-3 protein sigma  x x 
27 Q96DR5 BPI fold-containing family A member 2  x x 
23 P09211 Glutathione S-transferase P  x x 
23 P04792 Heat shock protein beta-1 (HspB1) x x 
23 Q96DA0 Zymogen granule protein 16 homolog B x x 
20 P18510 Interleukin-1 receptor antagonist protein (IL-1RN)  x x 
19 P31025 Lipocalin 1  x x 
18 P01591 Immunoglobulin J chain x x 
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18 Q9UHA7 Interleukin-36 alpha  x x 
18 Q9UBC9 Small proline-rich protein 3  x x 
17 P27482 Calmodulin-like protein 3  x x 
17 P12273 Prolactin-inducible protein (PIP) x x 
17 P02810 Salivary acidic proline-rich phosphoprotein 1/2  x x 
16 P28325 Cystatin D  x x 
16 P09228 Cystatin-SA (Cystatin-2) x x 
16 P01037 Cystatin-SN (Cystain-SA-I) x x 
16 P01036 Cystatin-S (Cystatin-4)  x x 
16 P01034 Cystatin-C (Cystatin-3)  x x 
15 P07737 Profilin-1  x x 
15 Q01469 Fatty acid-binding protein x x 
13 P06702 Protein S100-A9 (Calgranulin-B) x x 
11 P01040 Cystatin-A (Cystatin-AS)  x x 
11 P05109 Protein S100-A8 (Calgranulin-A)  x x 
10 P07108 Acyl-CoA-binding protein (ACBP) x x 
8 P02814 
Submaxillary gland androgen-regulated protein 3B (Proline-rich peptide P-
B)  
x x 
7 P15515 Histatin-1 (Histidine-rich protein 1)  x x 
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4.2. Update of OralCard database 
 
A review of the literature of proteins related to neuropsiquiatric diseases was 
made. After this revision, a list with the names of the 56 proteins, UniprotKBAC 
code (obtained by http://www.uniprot.org), pathologies in which that protein arises 
increased or decreased relative to normal as well as information about the study 
was obtained (Annex 4). Using the Uniprot codes of these proteins a network of 
the biological processes in which these proteins are involved is shown in Figure 
19. 
 
Figure 19 - Network of human GO: Biological Processes. At bold are the most prominent 
processes. The small circles represents the proteins and the bigger the processes in which the 
proteins are involved. The lines represent the interactions. Image generated by Cytoscape 
(ClueGO+CluePedia) on June 22, 2015. 
The network of biological processes highlights a great commitment of the immune 
response in these pathologies, underlining the positive regulation of T cell 
activation and the positive regulation of osteoclasts. There are proteins involved in 
Parkinson’s disease (PD), in neurotransmission (peptidyl-serine phosphorylation) 
and in allograft rejection. There are also proteins involved in semaphorin 
interaction. Semaphorins are a family of glicoproteins that mediate many cell 
processes critical to the immune system including cell-cell contact, migration and 
cytokine secretion [161]. Altered expression and function of semaphorin family 
members are associated with neurologic disorders and regenerative failure 
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following central nervous system injury [162]. Since that network is very complex, 
a detailed pie chart of the biological processes is made with the name of the 
proteins involved in a given process (Figure 20). 
 
 
Figure 20 – Pie chart of the human GO: Biological Processes. At dark blue we have the allograft 
rejection, at light green the positive regulation of osteoclast differentiation, at dark green the 
positive regulation of T cell activation, at grey the semaphoring interactions and at light blue the 
peptidyl-serine phosphorylation. The ** represents that there are a statistical significance of 
enrichment; the proteins presented in these processes are significantly increased in relation to the 
others.  Image generated by Cytoscape (ClueGO+CluePedia) on June 22, 2015. 
 
With this result we have more detailed information on the proteins and biological 
processes. For example, some proteins like TNF and interferon G appear in three 
processes, in the allograft rejection, peptidyl-serine phosphorylation and positive 
regulation of osteoclast differentiation. 
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After that, a network of Wikipathways represented on ClueGO+CluePedia was 
made (Figure 21). This network shows the processes and pathways in which the 
proteins are involved, namely the synaptic vesicle and PD and differentiation 
pathway as well as the cardiac hypertrophic response and allograft rejection. 
 
Figure 21- Wikipathways network. At bold are the most prominent processes. The small circles 
represents the proteins and the larger the processes in which the proteins are involved. The lines 
represent the interactions. Image generated by Cytoscape (ClueGO+CluePedia) on June 22, 2015. 
In ADHD the lack of nutrients is a problem and a proper nutrition is essential for 
ADHD treatment. In this network the vitamin B12 metabolism, the selenium 
micronutrient network and the folate metabolism are evidenced. The low levels of 
folate during pregnancy are related with hyperactivity in children. Deficiencies in 
folate and vitamin B12 have been associated with neurodegenerative diseases 
[163], like vascular dementia, AD and PD [164].  Selenium has also been identified 
as playing a role in several neurodegenerative disorders, including AD and PD 
[165].  
A network of Kyoto Encyclopedia of Genes and Genomes on ClueGO+CluePedia 
was also made (Figure 22). 
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Figure 22- Network of Kyoto Encyclopedia of Genes and Genomes represented on CluePedia. 
The small circle represents the proteins and the larger circles the diseases and processes in which 
the proteins are involved. The lines represent the interactions. Image generated by Cytoscape 
(ClueGO+CluePedia) on June 22, 2015. 
 
By the analysis of this network, the majority of the proteins are involved in a variety 
of diseases, namely PD, inflammatory bowel disease, asthma, rheumatoid arthritis 
and others. Some proteins are involved in the inflammatory response, highlighting 
the interleukin network and some pathways like the T cell receptor signaling 
pathway and the Janus kinase/signal transducers and activators of transcription 
(Jak-STAT) signaling pathway. The JAK/STAT pathway is the main signaling 
mechanism for a wide array of cytokines and growth factors used to transduce a 
multitude of signals for development and homeostasis. JAK activation stimulates 
cell proliferation, differentiation, cell migration and apoptosis. The cellular events 
are critical to hematopoiesis, immune development, sexually dimorphic growth and 
other processes. Mutations that constitutively activate or fail to regulate JAK 
signaling properly cause inflammatory disease and leukemia [166]. The JAK/STAT 
pathway implies an inflammatory base, in this case the PD.  This pathology is 
associated with elevated levels of cytokines that activate the JAK/STAT pathway 
[167]. A study indicates that the JAK/STAT pathway is inappropriately activated in 
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PD, which leads to neuroinflammation and neuronal damage. The inhibition of this 
pathway will be of benefit to PD patients [167].  
The network of Imune system represented on ClueGO+CluePedia was also made 
(Figure 23). 
 
 
 
Figure 23- Network of Imune system represented on CluePedia. The small circles represents the 
proteins and the bigger the processes in which the proteins are involved. The lines represent the 
different interactions. Image generated by Cytoscape (ClueGO+CluePedia) on June 22, 2015. 
 
In this network, we see the involvement of the proteins in the immune response in 
a greater detail. We see the interleukin network, and the proteins IL-2, IL-10, 
interferon G, IL-17, IL-4 and TNF present in this network are the same proteins 
found in the allograft rejection. With this information, it is possible that the 
inflammatory process lead to an auto immune response in ADHD. 
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4.3. Quantitative assessment of CCL13 and CCL3 in saliva samples from 
ADHD, dyslexic and healthy individuals  
 
Once the saliva SOP was established a quantitative assessment of the expression 
of two chemokines associated with inflammation quantified in saliva from patients 
with ADHD, dyslexia and ADHD with dyslexia was done.   
First, the protein concentration, volume and pH of saliva samples of healthy, 
hyperactive, dyslexic and hyperactive individuals with dyslexia were determined 
(27 samples in total). The hyperactivity, healthy, dyslexia and hyperactivity with 
dyslexia groups were compared in terms of total volume (Figure 24A), protein 
concentration (Figure 24B) and pH (Figure 24C). There is no statistical 
significance between samples.  
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Figure 24- Comparison between the four groups considering the Volume of saliva collected (A), 
Protein Concentration (B) and pH (C). Statistical significance was determined by Kruskal-Wallis 
test of one-Way ANOVA. Data from 27 subjects. 
The protein profiles of individuals with hyperactivity, dyslexia, hyperactivity with 
dyslexia and healthy were compared. For that, we determined the protein profiles 
of the 27 individuals.  The results from the capillary electrophoresis are shown on 
Figure 25: protein electrophoretic profile of healthy individuals (Figure 25, lanes 1-
8), protein electrophoretic profile of dyslexic individuals (Figure 25, lanes 9-13), 
protein electrophoretic profile of hyperactive individuals with dyslexia (Figure 25, 
lanes 14-18) and protein electrophoretic profile of hyperactive individuals (Figure 
25, lanes 19-27). 
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Figure 25- Protein profile from twenty seven saliva samples donors analysed by capillary 
electrophoresis using the Experion BioRad System. The protein electrophoretic profile is shown: 
healthy individuals (lanes 1-8), dyslexic individuals (lanes 9-13), hyperactive individuals with 
dyslexia (lanes 14-18) and hyperactive individuals (lanes 19-27). Ladder (L) with a range from 10 to 
150 kDa.  
In order to identify groups of profiles that may correspond to each clinical 
condition, the electrophoretic profile of the 27 samples is shown on Figure 26 
according to the MW and protein concentration. This analysis, and probably 
related to the reduced number of available samples, shows that there is no typical 
profile of the clinical situations. However by examining the most common profiles 
of each of the four groups there are differences visible in the profiles and it seems 
that there is a slight difference between the typical profiles of each group. 
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Figure 26- Heatmap visualizing the level of 36 bands differentially represented between subjects. 
Each column represents the data of protein concentration for all the subjects. Individuals 1- 8 are 
healthy, individuals 9-13 are dyslexic, individuals 14-18 are hyperactive with dyslexia and 
individuals 19-27 are hyperactive. Rows represent the different MW. The color code is graduated 
from black (under-representation compared to the group mean) to grey (over-representation 
compared to the group mean). Hierarchical clustering analysis was used to organize the map. The 
Cluster was done with the PermutMatrix program using the Ward's minimum variance method 
(n=27).  
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Protein concentration for each MW (protein band) in different individuals was 
compared using a non-parametric Kruskal-Wallis test of one-way ANOVA. These 
results, from the non-parametric Kruskal-Wallis test of one-way ANOVA show that 
the proteins with the molecular weights of 30, 35 and 200kDa) are significantly 
different (p<0.05) between individuals (Annex 5). To see what are the differences 
identified previously by the Kruskal Wallis test, the Dunn's Multiple Comparison 
test of one-Way ANOVA (Table 2) comparing the mean of the three groups 
(hyperactivity, dyslexia and hyperactivity with dyslexia group) with the mean of the 
control group (healthy group) shows that there are significant differences between 
the healthy and the hyperactivity with dyslexia group in the MW of 35 kDa and 200 
kDa (p<0.05). Between the healthy and the hyperactivity group there are also 
statistically significant differences in the bands with 30kDa and 200 kDa (p<0.05). 
Between the healthy and dyslexia group there is also statistical differences in the 
bands with 30kDa and 200 kDa (p<0.05). 
 
Table 2- Comparison between the four groups (healthy, hyperactivity, dyslexia and hyperactivity 
with dyslexia group) in terms of protein concentration correspondent to each band of the total 
protein profile obtained by capillary electrophoresis.  
 
With this analysis, we concluded that the bands with the MW 30, 35 and 200 kDa 
are the most variable between the different clinical situations. In the 
multicompromised individuals the bands with 35 and 200 are the more variables. 
Between all the groups the most variable are the band with 200 kDa. This implies 
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that the proteins localized in these MW bands are the most different between the 
clinical situations. The proteins identified by MS whose molecular weight is close 
to the proteins of interest (30, 35 and 200 kDa) are shown in table 3. 
 
Table 3- Proteins identified by Mass Spectrometry analysis, according to the MW and Uniprot 
code. 
 
 
After the analysis of proteins and corresponding bibliography, we conclude that 
these conditions have an underlying inflammatory response. Therefore, we 
analyzed two chemokines involved in inflammation. Two saliva chemokines (CCL3 
and CCL13) were quantified in 27 saliva samples of healthy, hyperactive, dyslexic 
and hyperactive children with dyslexia. Using the multiplex technique we are able 
to quantify the two chemokines on saliva samples.  
Results show significant differences between the protein concentration of samples 
from the 4 groups under study (Kruskal Wallis test for protein concentration of 
CCL3, p<0.05 and CCL13, p<0.05; Figures 27 A and B). Then, a Dunn’s multiple 
comparison test was done to understand these differences. CCL3 is significantly 
increased in the samples from the hyperactive group with dyslexia (when 
compared to the control group; p<0.01; Figure 27A). The same trend was found 
for CCL13: increase in the samples from the hyperactive group with dyslexia 
(p<0.05; Figure 27B). 
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These results show that CCL3 and CCL13 are increased only in the multi 
compromised group. Despite not having a sufficient number of samples for a solid 
statistical treatment, we see that the hyperactive group has the levels of these two 
cytokines increased nearly five times. There is an increase in the protein 
concentration in both proteins from 10 pg/mL in the healthy group to 50 pg/mL in 
the hyperactive group. 
This work shows for the first time that it is possible to evaluate these two 
chemokines, CCL3 and CCL13 in saliva, whereas others authors report zero 
values for CCL3 on saliva samples using Multiplex technology [168].  
 
 
Figure 27- Comparison between the four groups considering the protein concentration of CCL3 (A) 
and the protein concentration of CCL13 (B). Statistical significance was determined by Dunnett’s 
Multiple Comparison test of one-Way ANOVA. 
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The pro inflammatory chemokines CCL3 and CCL13 were quantified in saliva due 
to the fact that these proteins are increased in psychiatric and neurological 
disorders such as AD, epilepsy and autoimmune encephalomyelitis. 
CCL13, during chronic inflammation, is expressed in nonlymphoid tissues and acts 
as a chemotactic factor to attract monocytes in tissues exposed to exogenous 
pathogens [169]. CCL3 plays a role in recruiting macrophages, dendritic cells and 
T cells to site of infection and lymphoid organs [170] Previous studies suggest that 
this chemokine levels are associated with a stronger Th1 response [171] and has 
been implicated in suppression of hematopoietic stem and progenitor cell 
proliferation [172] 
The children that participate in our study manifest inflammation since the values of 
these two chemokines are increased which can indicate that neuroinflammation 
can be present in these pathologies. 
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5. Conclusion 
The saliva sample collection brings together a number of advantageous 
characteristics that allows us evaluate the pathologies by molecular biology 
methods, like electrophoresis, western blot, Enzyme-Linked Immunosorbent Assay 
and multiplex technology. We created a protocol for collection of whole saliva 
based on cotton-roll placed sublingually that is easy and inexpensive and 
produces samples suitable for protein analysis. The samples have sufficient 
quality and protein concentration to be stored by the Universidade Católica 
Portuguesa and associated IMM Biobank. We also were able to demonstrate that 
the SOP and the multiplex technique are established for these samples of ADHD 
and dyslexia. This technology and protocol can be used for other pathologies 
using a small quantity of saliva samples. 
Further research and validation studies of other possible inflammatory markers are 
needed for a better comprehension of these pathologies.  
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7. Annexes 
Are available as annexes the informed consent (Annex 1) and questionnaire 
(Annex 2) given to donors before the collection of saliva samples, the protocol of 
sublingual saliva collection, processing and storage (Annex 3), a table with the list 
of the reviewed proteins identified in neuropsychiatric disorders (Annex 4) and the 
table with the Kruskal-Wallis statistical analysis (Annex 5). 
. 
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7.3 Annex 3: Protocol for collection, processing and storing saliva 
samples 
80 
 
7.4 Annex 4: Review of the literature of proteins related to neuropsiquiatric diseases. 
List with the 56 proteins, uniprotKBAC code (obtained by http://www.uniprot.org). 
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unstimulated 
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independent 
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Dyslexia susceptibility 1 
candidate - dyx1c1 
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of Brain non-proteomics 12954984 
Q16552 IL-17 
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sapiens 
(Human)   
   
x 
 
x Autism 
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4 77M 
collection in 
acid-citrate-
dextrose 
Vacutainers ELISA non-proteomics 19800697 
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x 
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regulated 
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collection in 
acid-citrate- ELISA non-proteomics 19800697 
82 
 
(Human) dextrose 
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P20783 Neurotrophin-3 (NT-3) 
Homo 
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IGF1 Insulin-like growth 
factor I 
Homo 
sapiens 
(Human)   
 
x 
   
x Autism 
Down-
regulated 1-15 20M/5F 
 
radio immunoassay non-proteomics 16904022 
P01344 
IGF2 Insulin-like growth 
factor II 
Homo 
sapiens 
(Human)   
 
x 
   
x Autism 
 
1-15 20M/5F 
 
radio immunoassay non-proteomics 16904022 
P34130 Neurotrophin -4/5 
Homo 
sapiens 
(Human)   
    
x x Autism 
   
Blood drawn ELISA, xMAP Luminex non-proteomics 16289943 
Q9NPY3 Complement C1q 
Homo 
sapiens 
(Human)   
  
x 
  
x Autism 
Up-
regulated 4-6 
 
Blood draw LC-ESI-MS on TOF proteomics 17189958 
P02751 Fibronectin 1 
Homo 
sapiens 
(Human)   
  
x 
  
x Autism 
 
4-6 
 
Blood draw LC-ESI-MS on TOF Proteomics 17189958 
P06727 Apolipoprotein A-IV 
Homo 
sapiens 
(Human)   
  
x 
  
x Autism 
Up-
regulated 4-6 
 
Blood draw LC-ESI-MS on TOF Proteomics 17189958 
P04114 Apolipoprotein B-100 
Homo 
sapiens 
(Human)   
  
x 
  
x Autism 
Up-
regulated 4-6 
 
Blood draw LC-ESI-MS on TOF Proteomics 17189958 
Q03591 
Complement factor H -
related protein 
Homo 
sapiens 
(Human)   
  
x 
  
x Autism 
 
4-6 
 
Blood draw LC-ESI-MS on TOF Proteomics 17189958 
P62258 
Chain A, 14-3-3 Protein 
Epsilon 
Mus 
musculus 
(Mouse)   x 
     
Attention deficit hyperactivity disorder 
(ADHD) 
Dissection of 
brain and 
separation of 
cortex, 
striatum and 
midbrain on 
ice 
Two-dimensional gel 
electrophoresis, Peptide 
mass fingerprinting/tandem 
mass spectrometry, RT-PCR, 
western blot 
mass fingerprinting/tandem 
mass spectrometry 
Proteomics and 
Transcriptomics 18457438 
Q16555 
Dihydropyrimidinase 
related protein-2 (DRP-2) 
Mus 
musculus 
(Mouse)   x 
     
Attention deficit hyperactivity disorder 
(ADHD) 
Dissection of 
brain and 
separation of 
cortex, 
striatum and 
midbrain on 
ice 
Two-dimensional gel 
electrophoresis, Peptide 
mass fingerprinting/tandem 
mass spectrometry, RT-PCR, 
western blot 
mass fingerprinting/tandem 
mass spectrometry 
Proteomics and 
Transcriptomics 18457438 
Q14195 
Collapsin response 
mediator protein 4 
(CRMP4) 
Mus 
musculus 
(Mouse)   x 
     
Attention deficit hyperactivity disorder 
(ADHD) 
Dissection of 
brain and 
separation of 
cortex, 
Two-dimensional gel 
electrophoresis, Peptide 
mass fingerprinting/tandem 
mass spectrometry, RT-PCR, 
Proteomics and 
Transcriptomics 18457438 
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striatum and 
midbrain on 
ice 
western blot 
mass fingerprinting/tandem 
mass spectrometry 
P63104 14-3-3 Protein Zeta 
Mus 
musculus 
(Mouse)   x 
     
Attention deficit hyperactivity disorder 
(ADHD) 
Dissection of 
brain and 
separation of 
cortex, 
striatum and 
midbrain on 
ice 
Two-dimensional gel 
electrophoresis, Peptide 
mass fingerprinting/tandem 
mass spectrometry, RT-PCR, 
western blot 
mass fingerprinting/tandem 
mass spectrometry 
Proteomics and 
Transcriptomics 18457438 
P30086 
Phosphatidylethanolamine 
binding protein 
Mus 
musculus 
(Mouse)   x 
     
Attention deficit hyperactivity disorder 
(ADHD) 
Dissection of 
brain and 
separation of 
cortex, 
striatum and 
midbrain on 
ice 
Two-dimensional gel 
electrophoresis, Peptide 
mass fingerprinting/tandem 
mass spectrometry, RT-PCR, 
western blot 
mass fingerprinting/tandem 
mass spectrometry 
Proteomics and 
Transcriptomics 18457438 
P49789 
Fragile histidine triad 
protein (Fhit) 
Mus 
musculus 
(Mouse)   x 
     
Attention deficit hyperactivity disorder 
(ADHD) 
Dissection of 
brain and 
separation of 
cortex, 
striatum and 
midbrain on 
ice 
Two-dimensional gel 
electrophoresis, Peptide 
mass fingerprinting/tandem 
mass spectrometry, RT-PCR, 
western blot 
mass fingerprinting/tandem 
mass spectrometry 
Proteomics and 
Transcriptomics 18457438 
P11216 
Brain glycogen 
phosphorylase 
Mus 
musculus 
(Mouse)   x 
     
Attention deficit hyperactivity disorder 
(ADHD) 
Dissection of 
brain and 
separation of 
cortex, 
striatum and 
midbrain on 
ice 
Two-dimensional gel 
electrophoresis, Peptide 
mass fingerprinting/tandem 
mass spectrometry, RT-PCR, 
western blot 
mass fingerprinting/tandem 
mass spectrometry 
Proteomics and 
Transcriptomics 18457438 
P18669 
Phosphoglycerate mutase 
1 (PGM1) 
Mus 
musculus 
(Mouse)   x 
     
Attention deficit hyperactivity disorder 
(ADHD) 
Dissection of 
brain and 
separation of 
cortex, 
striatum and 
midbrain on 
ice 
Two-dimensional gel 
electrophoresis, Peptide 
mass fingerprinting/tandem 
mass spectrometry, RT-PCR, 
western blot 
mass fingerprinting/tandem 
mass spectrometry 
Proteomics and 
Transcriptomics 18457438 
P60174 
Triosephosphate 
isomerase (Tpi) 1 protein 
Mus 
musculus 
(Mouse)   x 
     
Attention deficit hyperactivity disorder 
(ADHD) 
Dissection of 
brain and 
separation of 
cortex, 
striatum and 
midbrain on 
ice 
Two-dimensional gel 
electrophoresis, Peptide 
mass fingerprinting/tandem 
mass spectrometry, RT-PCR, 
western blot 
mass fingerprinting/tandem 
mass spectrometry 
Proteomics and 
Transcriptomics 18457438 
P08559 
Pyruvate dehydrogenase 
E1 alpha 1 
Mus 
musculus   x 
     
Attention deficit hyperactivity disorder 
(ADHD) 
Dissection of 
brain and 
Two-dimensional gel 
electrophoresis, Peptide 
Proteomics and 
Transcriptomics 18457438 
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(Mouse) separation of 
cortex, 
striatum and 
midbrain on 
ice 
mass fingerprinting/tandem 
mass spectrometry, RT-PCR, 
western blot 
mass fingerprinting/tandem 
mass spectrometry 
O00429 D100 (Dynamin 1) 
Mus 
musculus 
(Mouse)   x 
     
Attention deficit hyperactivity disorder 
(ADHD) 
Dissection of 
brain and 
separation of 
cortex, 
striatum and 
midbrain on 
ice 
Two-dimensional gel 
electrophoresis, Peptide 
mass fingerprinting/tandem 
mass spectrometry, RT-PCR, 
western blot 
mass fingerprinting/tandem 
mass spectrometry 
Proteomics and 
Transcriptomics 18457438 
Q9H115 
N-ethylmaleimide 
sensitive fusion protein 
attachment protein 
(SNAP)-beta 
Mus 
musculus 
(Mouse)   x 
     
Attention deficit hyperactivity disorder 
(ADHD) 
Dissection of 
brain and 
separation of 
cortex, 
striatum and 
midbrain on 
ice 
Two-dimensional gel 
electrophoresis, Peptide 
mass fingerprinting/tandem 
mass spectrometry, RT-PCR, 
western blot 
mass fingerprinting/tandem 
mass spectrometry 
Proteomics and 
Transcriptomics 18457438 
P61764 Syntaxin binding protein 1 
Mus 
musculus 
(Mouse)   x 
     
Attention deficit hyperactivity disorder 
(ADHD) 
Dissection of 
brain and 
separation of 
cortex, 
striatum and 
midbrain on 
ice 
Two-dimensional gel 
electrophoresis, Peptide 
mass fingerprinting/tandem 
mass spectrometry, RT-PCR, 
western blot 
mass fingerprinting/tandem 
mass spectrometry 
Proteomics and 
Transcriptomics 18457438 
P22676 Calbindin 2 (Calretinin) 
Mus 
musculus 
(Mouse)   x 
     
Attention deficit hyperactivity disorder 
(ADHD) 
Dissection of 
brain and 
separation of 
cortex, 
striatum and 
midbrain on 
ice 
Two-dimensional gel 
electrophoresis, Peptide 
mass fingerprinting/tandem 
mass spectrometry, RT-PCR, 
western blot 
mass fingerprinting/tandem 
mass spectrometry 
Proteomics and 
Transcriptomics 18457438 
P49411 
Tu translation elongation 
factor (EF-Tu) 
Mus 
musculus 
(Mouse)   x 
     
Attention deficit hyperactivity disorder 
(ADHD) 
Dissection of 
brain and 
separation of 
cortex, 
striatum and 
midbrain on 
ice 
Two-dimensional gel 
electrophoresis, Peptide 
mass fingerprinting/tandem 
mass spectrometry, RT-PCR, 
western blot 
mass fingerprinting/tandem 
mass spectrometry 
Proteomics and 
Transcriptomics 18457438 
P05388 
Acidic ribosomal 
phosphoprotein PO 
Mus 
musculus 
(Mouse)   x 
     
Attention deficit hyperactivity disorder 
(ADHD) 
Dissection of 
brain and 
separation of 
cortex, 
striatum and 
midbrain on 
ice 
Two-dimensional gel 
electrophoresis, Peptide 
mass fingerprinting/tandem 
mass spectrometry, RT-PCR, 
western blot 
mass fingerprinting/tandem 
mass spectrometry 
Proteomics and 
Transcriptomics 18457438 
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Q99719 CDCrel-1AI 
Mus 
musculus 
(Mouse)   x 
     
Attention deficit hyperactivity disorder 
(ADHD) 
Dissection of 
brain and 
separation of 
cortex, 
striatum and 
midbrain on 
ice 
Two-dimensional gel 
electrophoresis, Peptide 
mass fingerprinting/tandem 
mass spectrometry, RT-PCR, 
western blot 
mass fingerprinting/tandem 
mass spectrometry 
Proteomics and 
Transcriptomics 18457438 
Q14568 
Heat shock protein HSP 
90-alpha 
Mus 
musculus 
(Mouse)   x 
     
Attention deficit hyperactivity disorder 
(ADHD) 
Dissection of 
brain and 
separation of 
cortex, 
striatum and 
midbrain on 
ice 
Two-dimensional gel 
electrophoresis, Peptide 
mass fingerprinting/tandem 
mass spectrometry, RT-PCR, 
western blot 
mass fingerprinting/tandem 
mass spectrometry 
Proteomics and 
Transcriptomics 18457438 
P09172 
protein dopamine-b-
hydroxylase 
Homo 
sapiens 
(Human)   
   
x 
  
Attention 
deficit 
hyperactivity 
disorder 
(ADHD) Down-regulated 
   
non-proteomics 17187001 
P0C0L5 complement C4B protein   
   
x 
 
x 
Attention 
deficit 
hyperactivity 
disorder 
(ADHD) 
Down-
regulated 4-19 19M/4F 
Blood 
collection ELISA non-proteomics 7665439 
P30086 PEBP 
Mus 
musculus 
(Mouse)   x 
     
Attention deficit hyperactivity disorder (ADHD) 
Electrophoresis 2D, RT-PCR, 
MALDI-TOF-MS 
Proteomics and 
Transcriptomics 22231835 
P35638 CHOP 
Mus 
musculus 
(Mouse)   x 
     
Attention deficit hyperactivity disorder (ADHD) 
Electrophoresis 2D, RT-PCR, 
MALDI-TOF-MS 
Proteomics and 
Transcriptomics 22231835 
P30101  Grp58 
Mus 
musculus 
(Mouse)   x 
     
Attention deficit hyperactivity disorder (ADHD) 
 
Proteomics 20109102 
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7.5 Annex 5: Band to band Kruskal-Wallis statistical analysis  
 
